CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art

CLEOPATRA & EMILIA: HER2+ mBC state-of-the-artПодробнее

CLEOPATRA: Success With Dual HER2 Blockade in Breast CancerПодробнее

CLEOPATRA: Treating HER2-Positive Breast CancerПодробнее

CLEOPATRA Trial: Pertuzumab Regimen for Frontline HER2-Positive Metastatic Breast CancerПодробнее

Dual HER2 Blockade Defers Breast Cancer in CLEOPATRAПодробнее

EMILIA Trial: T-DM1 in Metastatic Breast CancerПодробнее

Evolving Treatment Landscape of R/R HER2+ mBCПодробнее

HER2+ MBC | 2023 Best of Breast ConferenceПодробнее

CLEOPATRA: changes in breast cancer natural historyПодробнее

Sequencing of Therapy in R/R HER2+ mBCПодробнее

Dr. Blackwell on the Impact of the CLEOPATRA and MARIANNE Studies in HER2+ Breast CancerПодробнее

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA StudyПодробнее

State of the art in the systemic therapy of her positive metastatic breast cancer | George RigakosПодробнее

SOPHIA Trial in R/R HER2+ mBCПодробнее

Evolving Treatment Landscape of R/R HER2+ mBCПодробнее

Cleopatra Suffered Two Calamitous Events in One YearПодробнее

HER2CLIMB and NALA Trials: R/R HER2+ mBCПодробнее

ASCO 2012: Primary Results from EMILIA Breast Cancer TrialПодробнее

Dr. Perez Discusses the CLEOPATRA Pertuzumab TrialПодробнее